Skip to NavigationSkip to content

News

0
EUSA Pharma gets FDA green light to evaluate IL-6 inhibitor siltuximab in COVID-19 patients
EUSA Pharma has announced that the FDA has given the go-ahead for randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate its...
0
COVID-19 immunity may be more widespread than previously thought, new study suggests
Coronavirus immunity in the world’s population may be more widespread than initially thought, even in those who have tested negative for antibodies,...
0
European Commission announces approval for Janssen’s Ebola vaccine
Johnson & Johnson announced that the European Commission has granted Marketing Authorisation for its Janssen Ebola vaccine.
0
Drug industry suing to overturn Minnesota insulin affordability law
The drug industry is suing to overturn a Minnesota law that requires companies to provide emergency insulin to diabetics who can’t afford it.
>> More News Stories

Features

How is COVID-19 impacting the rare disease community?

The COVID-19 pandemic has altered the life of just about everyone, especially patients in receiving continued treatment and care. But what does it...

>> More Features
>> More News Stories